Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells

References

• De Rosa M, Pace U, Rega D, Costabile V, Duraturo F Izzo P and Delrio P. Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. 2015;34:1087–1096. doi:10.3892/or.2015.4108.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Lynch JF Lynch PM and Attard T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam Cancer. 2008;7:27–39. doi:10.1007/s10689-007-9165-5.
   PubMed Web of Science ®Google Scholar
• Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13:120–135. doi:10.28092/j.issn.2095-3941.2015.0103.
   PubMed Web of Science ®Google Scholar
• Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ Tveit KM and Gibson F. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1–10. doi:10.1016/j.clcc.2014.11.002.
   PubMed Web of Science ®Google Scholar
• El Zouhairi M Charabaty A and Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res.2011;4:15–21.
   PubMedGoogle Scholar
• Tabernero J, Salazar R, Casado E, Martinelli E. Gomez P and Baselga J. Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol. 2004;15(Suppl 4):iv55–62. doi:10.1093/annonc/mdh905.
   PubMedGoogle Scholar
• Al-Salama ZT Garnock-Jones KP and Scott LJ. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma. Target Oncol. 2017;12:535–542. doi:10.1007/s11523-017-0504-7.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Gentili S Maracci L and Leoni P. Oral ixazomib maintenance therapy in multiple myeloma. Expert Rev Anticancer Ther. 2016;16:21–32. doi:10.1586/14737140.2016.1123627.
   PubMed Web of Science ®Google Scholar
• Salvini M, Troia R, Giudice D, Pautasso C Boccadoro M and Larocca A. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. 2018;14:91–99. doi:10.1080/17425255.2018.1417388.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D van de Velde H and Moreau P. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. J Blood Med. 2017;8:107–121. doi:10.2147/JBM.S102328.
   PubMed Web of Science ®Google Scholar
• Augello G, Modica M, Azzolina A, Puleio R, Cassata G, Emma MR, Di Sano C, Cusimano AMontalto G and Cervello M. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells. Cell Death Dis. 2018;9:28. doi:10.1038/s41419-017-0195-0.
   PubMed Web of Science ®Google Scholar
• Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, et al.. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;7:81172–81186. doi:10.18632/oncotarget.12791.
   PubMedGoogle Scholar
• Engur S, Dikmen M. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib. Acta Clin Belg. 2017;72:391–398. doi:10.1080/17843286.2017.1302623.
   PubMed Web of Science ®Google Scholar
• Fan Q, Liu B. Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis. Onco Targets Ther. 2017;10:3591–3606. doi:10.2147/OTT.S139686.
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell Mol Life Sci. 2016;73:79–94. doi:10.1007/s00018-015-2052-6.
   PubMed Web of Science ®Google Scholar
• Phillips MJ, Voeltz GK. Structure and function of ER membrane contact sites with other organelles. Nat Rev Mol Cell Biol. 2016;17:69–82. doi:10.1038/nrm.2015.8.
   PubMed Web of Science ®Google Scholar
• Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173–194. doi:10.1146/annurev-pathol-012513-104649.
   PubMed Web of Science ®Google Scholar
• Cnop M, Toivonen S Igoillo-Esteve M and Salpea P. Endoplasmic reticulum stress and eIF2alpha phosphorylation: the Achilles heel of pancreatic beta cells. Mol Metab. 2017;6:1024–1039. doi:10.1016/j.molmet.2017.06.001.
   PubMed Web of Science ®Google Scholar
• Leitman J, Barak B, Benyair R, Shenkman M, Ashery U Hartl FU and Lederkremer GZ. ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PLoS One. 2014;9:e90803. doi:10.1371/journal.pone.0090803.
   PubMed Web of Science ®Google Scholar
• Iurlaro R, Munoz-Pinedo C. Cell death induced by endoplasmic reticulum stress. FEBS J. 2016;283:2640–2652. doi:10.1111/febs.13598.
   PubMed Web of Science ®Google Scholar
• Anania VG, Yu K, Gnad F, Pferdehirt RR, Li H, Ma TP, Jeon D, Fortelny N, Forrest W, Ashkenazi A Overall CM and Lill JR. Uncovering a Dual Regulatory Role for Caspases During Endoplasmic Reticulum Stress-induced Cell Death. Mol Cell Proteomics. 2016;15:2293–2307. doi:10.1074/mcp.M115.055376.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhan D, Wang L, Ma D, Cheng M, Wang H, Zhao J Cai Y and Cheng Z. Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway. Oncol Rep. 2016;36:845–852. doi:10.3892/or.2016.4839.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y Miki T and Sakai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005;65:5662–5667. doi:10.1158/0008-5472.CAN-05-0693.
   PubMed Web of Science ®Google Scholar
• Liu X, Yue P, Chen S, Hu L, Lonial S Khuri FR and Sun SY. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67:4981–4988. doi:10.1158/0008-5472.CAN-06-4274.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798–4811. doi:10.1038/sj.onc.1209608.
   PubMed Web of Science ®Google Scholar
• Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009;122:437–441. doi:10.1242/jcs.031682.
   PubMed Web of Science ®Google Scholar
• Martinou JC, Youle RJ. Mitochondria in apoptosis: bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011;21:92–101. doi:10.1016/j.devcel.2011.06.017.
   PubMed Web of Science ®Google Scholar
• Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 2011;60:1173–1180. doi:10.1007/s00262-011-1008-4.
   PubMed Web of Science ®Google Scholar
• Naimi A, Movassaghpour AA, Hagh MF, Talebi M, Entezari A Jadidi-Niaragh F and Solali S. TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. Biomed Pharmacother. 2017;98:566–576. doi:10.1016/j.biopha.2017.12.082.
   PubMed Web of Science ®Google Scholar
• Siegmund D Lang I and Wajant H. Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. FEBS J. 2017;284:1131–1159. doi:10.1111/febs.13968.
   PubMed Web of Science ®Google Scholar
• Bertsch U, Roder C Kalthoff H and Trauzold A. Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2. Cell Death Dis. 2014;5:e1390. doi:10.1038/cddis.2014.351.
   PubMed Web of Science ®Google Scholar
• Moriwaki K, Chan FK. Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome. J Biol Chem. 2016;291:5948–5959. doi:10.1074/jbc.M115.700997.
   PubMed Web of Science ®Google Scholar
• Svandova EB, Vesela B, Lesot H Poliard A and Matalova E. Expression of Fas, FasL, caspase-8 and other factors of the extrinsic apoptotic pathway during the onset of interdigital tissue elimination. Histochem Cell Biol. 2017;147:497–510. doi:10.1007/s00418-016-1508-6.
   PubMed Web of Science ®Google Scholar
• Pobezinskaya YL, Liu Z. The role of TRADD in death receptor signaling. Cell Cycle. 2012;11:871–876. doi:10.4161/cc.11.5.19300.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004;279:45495–45502. doi:10.1074/jbc.M406933200.
   PubMed Web of Science ®Google Scholar
• Tiwary R, Yu W, Li J, Park SK Sanders BG and Kline K. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010;5:e11865. doi:10.1371/journal.pone.0011865.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446. doi:10.1158/0008-5472.CAN-09-1947.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG. Group T-MS,Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374:1621–1634. doi:10.1056/NEJMoa1516282.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, et al.. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15:1503–1512. doi:10.1016/S1470-2045(14)71125-8.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, et al.. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. Placebo-Lenalidomide-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma in TOURMALINE-MM1. Haematologica. 2017;102:1767–1775.
   Google Scholar
• Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017;8:209–220. doi:10.1177/2040620717710171.
   PubMed Web of Science ®Google Scholar
• Bonnet A, Moreau P. Safety of ixazomib for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017;16:973–980. doi:10.1080/14740338.2017.1344212.
   PubMed Web of Science ®Google Scholar
• Wang F Lin J and Xu R. The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs. Curr Pharm Des. 20;2014:6714–6722.
   PubMed Web of Science ®Google Scholar
• Sessler T, Healy S. Samali A and Szegezdi E. Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol Ther. 2013;140:186–199. doi:10.1016/j.pharmthera.2013.06.009.
   PubMed Web of Science ®Google Scholar
• Shlyakhtina YPavet V and Gronemeyer H. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis. 2017;8:e3025. doi:10.1038/cddis.2017.518.
   PubMed Web of Science ®Google Scholar
• Lei Y, Wang S, Ren B, Wang J, Chen J, Lu J, Zhan S, Fu YHuang L and Tan J. CHOP favors endoplasmic reticulum stress-induced apoptosis in hepatocellular carcinoma cells via inhibition of autophagy. PLoS One. 2017;12:e0183680. doi:10.1371/journal.pone.0183680.
   PubMed Web of Science ®Google Scholar
• Kim IY, Kang YJ, Yoon MJ, Kim EH, Kim SU, Kwon TKKim IA and Choi KS. Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011;13:267–279. doi:10.1093/neuonc/noq195.
   PubMed Web of Science ®Google Scholar